Given the expanding use of incretin-based therapies for obesity, clinicians should maintain a high index of suspicion for insulinoma in patients presenting with severe or persistent hypoglycemia. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.